Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.50 Consensus Target Price from Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $56.50.

AGIO has been the subject of several research reports. Wall Street Zen downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Scotiabank lowered their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research note on Friday, May 2nd. Finally, HC Wainwright began coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price objective for the company.

Insider Buying and Selling

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the transaction, the director now owns 149,220 shares of the company's stock, valued at approximately $3,864,798. The trade was a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Venturi Wealth Management LLC purchased a new position in Agios Pharmaceuticals in the fourth quarter valued at $33,000. GF Fund Management CO. LTD. purchased a new position in Agios Pharmaceuticals in the fourth quarter valued at $39,000. NewEdge Advisors LLC purchased a new position in Agios Pharmaceuticals in the first quarter valued at $40,000. CWM LLC increased its holdings in Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 996 shares in the last quarter. Finally, Wingate Wealth Advisors Inc. purchased a new position in Agios Pharmaceuticals in the fourth quarter valued at $53,000.

Agios Pharmaceuticals Trading Down 1.3%

Shares of NASDAQ:AGIO traded down $0.45 on Wednesday, hitting $33.58. 399,289 shares of the company were exchanged, compared to its average volume of 672,223. Agios Pharmaceuticals has a 1-year low of $23.42 and a 1-year high of $62.58. The stock's 50 day moving average price is $28.75 and its 200 day moving average price is $34.79. The firm has a market capitalization of $1.94 billion, a P/E ratio of 2.96 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, topping the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. The business had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.86 million. On average, equities analysts predict that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.